All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-22T10:44:27.000Z

ICML 2019 | What are the latest advances in the treatment of CLL?

Jun 22, 2019
Share:

Bookmark this article

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Hallek from University Hospital of Cologne, Cologne, DE, about the latest advances in the treatment of chronic lymphocytic leukemia (CLL).

Michael Hallek describes that latest therapy options emerging from recent research, focusing on monotherapies with ibrutinib being potent first-line therapies, along with the strong move towards chemotherapy-free combinations.

He described these novel agents as venetoclax, ibrutinib, and obinutuzumab, and said that they need to be further investigated as to whether all three are needed, or if a particular pair or combination works better.

What are the latest advances in the treatment of CLL?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox